- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05849493
Effects and Mechanisms of Change of Internet Delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder (ORIGAMI)
Effects and Mechanisms of Change of Internet Delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder Based on Intolerance of Uncertainty or Metacognitive Theory
The goal of this clinical trial is to compare two psychological treatments for Generalized Anxiety Disorder. The main questions it aims to answer are:
How well do these treatments work compared to earlier studies? Is one of the treatments more effective than the other? Are the treatments working the way that we think they do? Specifically, do changes in the variables that these treatments aim to target predict changes in anxiety symptoms?
Participants will be randomized to two different internet-based cognitive behavioral therapy (ICBT) programs: Intolerance of uncertainty-based ICBT and metacognition-based ICBT. Both programs consist of 8 treatment modules and run for 10 weeks. A psychologist will respond to the participants assignments and exercises and will respond to messages.
Study Overview
Status
Conditions
Detailed Description
A randomized trial will be conducted within the Internet Psychiatry Clinic in Stockholm. An option will be added to the online sign-up form giving potential patients the option to participate in a treatment for GAD as part of this study. Based on information provided in the sign-up-form and an assessment via video-call with a psychologist, patients will be included/excluded.
Included patients will be randomized (1:1) to two different ICBT treatment programs (IU-ICBT and Meta-ICBT). These programs will be implemented into regular care at the Internet Psychiatry Clinic in Stockholm, meaning that each patient will undergo the regular assessment process at the clinic. Both programs are ICBT programs of similar scope, consisting of 8 modules to be completed during 10 weeks. During this time patients read written material which instructs them to do specific exercises, answer specific questions and can message a psychologist at the clinic via the web-platform. Based on similar treatments on the Internet Psychiatry Clinic we expect around 10% drop-out.
The effectiveness of both forms of ICBT (meaning within-group change in symptoms during the ten-week treatment) will be compared to a meta-analysis of the effectiveness of traditional CBT for GAD (g = 0.80). When comparing the treatment programs to each other the threshold for a clinically relevant difference will be g = 0.24. A power analysis has shown that n=200 in each arm gives at least 80% power to detect an effect of that size.
Hypothesis 1: IU-ICBT and Meta-ICBT will be effective and equivalent in a benchmarking analysis.
Data-analysis: We plan to use multi-level modeling to utilize the increased power/precision we get from within-participant repeated measures.
Hypothesis 2: Changes in intolerance of uncertainty will statistically mediate the treatment effect in the IU-ICBT group. Changes in negative metacognitive beliefs about worry will statistically mediate the treatment effect in the Meta-ICBT group. The effect of both mediators will be moderated by level of intolerance uncertainty and negative metacognitive beliefs at baseline. We will also compare the putative mediators to each other with the hypothesis that the mediation-effect will be stronger for the specific mediator that a treatment protocol targets.
Data-analysis: Participants will fill out weekly questionnaires which will include our putative mediators (MCQ-30 and IU-12 questionnaires) and their current symptom level (GAD-7 questionnaire). The mediation-effect of both treatment protocols will be analyzed using latent growth curve modeling which is considered suitable for the study of moderation and mediation in clinical trials.
Additional hypotheses: In addition to the primary hypotheses, we may also investigate alternative moderators proposed by the literature. Worry behaviors is hypothesised to moderate treatment effect in the IU-ICBT group since that treatment partially has a behavioral treatment focus. Emotional contrast avoidance will also be investigated as a moderator.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Vilgot Huhn, MSc
- Phone Number: +46768482613
- Email: vilgot.huhn@ki.se
Study Contact Backup
- Name: Erik Forsell, PhD
- Phone Number: +46704903681
- Email: erik.forsell@ki.se
Study Locations
-
-
Huddinge
-
Stockholm, Huddinge, Sweden, 14135
- Recruiting
- Internet Psychiatry Clinic, Psychiatry Southwest, SLSO, Region Stockholm
-
Contact:
- Erik Forsell
- Phone Number: 0704903681
- Email: erik.forsell@ki.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria:
- 18 years or older.
- Meet diagnostic criteria for GAD according to DSM-5, as assessed by a psychologist on a video-call.
- Self-rated score > 10 on GAD-7.
- Can read and speak Swedish fluently.
- Have access to a smartphone, tablet, or computer and a Swedish BankID which allows access to the video-calls and treatment platform.
- Have the time and possibility to participate in the 10 week treatment.
- Consents to participate.
Exclusion criteria:
- Patients that are judged to be in greater need of another psychiatric treatment for another psychiatric diagnosis (for example severe depression) and/or is judged to have a high risk of suicide.
- Current drug or alcohol abuse.
- Current severe somatic health concern or social vulnerability if this is judged to be too great an obstacle for the patient to carry out the treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IU-ICBT
10 week program of internet delivered cognitive behavior therapy with written support by licensed clinical psychologist.
Based on the Intolerance of uncertainty model of worry.
|
Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry
|
Experimental: Meta-ICBT
10 week program of internet delivered cognitive behavior therapy with written support by licensed clinical psychologist.
Based on the Metacognitive model of worry.
|
Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Generalized Anxiety Disorder-7 score (GAD-7)
Time Frame: From treatment start to 10 weeks after treatment start
|
Measures Generalized Anxiety Symptoms.
7 items.
Scores range from 0-21 with higher scores indicating more generalized anxiety
|
From treatment start to 10 weeks after treatment start
|
Change in Meta-Cognitions Questionnaire-30 score (MCQ-30, negative meta-cognition sub-scale)
Time Frame: From treatment start to 10 weeks after treatment start
|
Putative mediator.
The MCQ-30 negative subscale measures negative meta-cognitive beliefs about the danger and uncontrollability of worry.
6 items.
Scores range from 6-36 with higher scores indicating more negative beliefs about worry.
|
From treatment start to 10 weeks after treatment start
|
Change in Intolerance of Uncertainty Scale-12 score (IUS-12)
Time Frame: From treatment start to 10 weeks after treatment start
|
Putative mediator, measures intolerance of uncertainty.
12 items.
Scores range from 12-60 with higher scores indicating more intolerance of uncertainty.
|
From treatment start to 10 weeks after treatment start
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Penn-State Worry Questionnaire (PSWQ)
Time Frame: 10 weeks - pre- and post-treatment.
|
Measures trait worry.
16 items.
Scores range from 16-80 with higher scores indicating more worry.
|
10 weeks - pre- and post-treatment.
|
Contrast Avoidance Questionnaire-Worry (CAQ-W)
Time Frame: 10 weeks - pre- and post-treatment.
|
measures Contrast Avoidance related to worry.
25 items.
Scores range from 30 to 150 with higher scores indicating a higher degree of using worry to avoid emotional contrasts.
|
10 weeks - pre- and post-treatment.
|
Montomery-Asberg Depression Rating Scale - Self-rated (MADRS-S)
Time Frame: 10 weeks - pre- and post-treatment.
|
Measures depression symptoms.
9 items.
Scores range from 0 to 54 with higher scores indicating more depressive symptoms.
|
10 weeks - pre- and post-treatment.
|
Meta-Cognitions Qquestionnaire-30 (MCQ-30 - full scale)
Time Frame: 10 weeks - pre- and post-treatment.
|
Measures metacognition.
30 items.
Scores range from 30-120 with higher scores indicating more potentially dysfunctional metacognitive beliefs about thoughts and worry.
|
10 weeks - pre- and post-treatment.
|
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 10 weeks - pre- and post-treatment.
|
Measures depression symptoms.
9 items.
Scores range from 0-27 with higher scores indicating more depressive symptoms.
|
10 weeks - pre- and post-treatment.
|
World Health Organization Disability Assessment Schedule 2.0
Time Frame: 10 weeks - pre- and post-treatment.
|
Measures disability/functional impairment.
12 items.
Scores range from 0-48 with higher scores indicating a higher degree of impairment.
|
10 weeks - pre- and post-treatment.
|
Client satisfaction questionnaire (adapted to the clinic)
Time Frame: 10 weeks after treatment start.
|
Measures satisfaction with treatment.
8 items.
Scores range from 8-32 with higher scores indicating more satisfaction with the treatment.
|
10 weeks after treatment start.
|
Worry Behavior Inventory (WBI)
Time Frame: 10 weeks - pre- and post-treatment.
|
Inventory of worry behaviors - 10 items.
Scores range from 0-40 with higher scores indicating more frequent worry behaviours.
|
10 weeks - pre- and post-treatment.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Erik Forsell, PhD, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-02380-01-RCT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Anxiety Disorder
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
-
Xijing HospitalRecruitingGeneralized Anxiety DisorderChina
-
Sichuan Jishengtang Pharmaceutical Co., Ltd.Not yet recruitingGeneralized Anxiety Disorder
-
Hospital de Clinicas de Porto AlegreRecruitingGeneralized Anxiety DisorderBrazil
-
University of California, Los AngelesMedical University of South Carolina; Massachusetts General HospitalRecruitingGeneralized Anxiety DisorderUnited States
-
Shahid Beheshti University of Medical SciencesCompletedGeneralized Anxiety DisorderIran, Islamic Republic of
-
Dr. Nazanin AlaviOnline PsychoTherapy ClinicCompletedGeneralized Anxiety DisorderCanada
-
Laureate Institute for Brain Research, Inc.National Institute of Mental Health (NIMH)CompletedGeneralized Anxiety DisorderUnited States
-
The Canadian College of Naturopathic MedicineMassachusetts General Hospital; McGill University; Mitacs; Ekhagastiftelsen; Netherlands... and other collaboratorsActive, not recruitingGeneralized Anxiety DisorderCanada
Clinical Trials on Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy
-
Karolinska InstitutetUppsala UniversityCompleted
-
Karolinska InstitutetCompletedIrritable Bowel Syndrome | Functional Gastrointestinal DisordersSweden
-
Linkoeping UniversityKarolinska Institutet; Uppsala University; Umeå University; Stockholm UniversityUnknownBrain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder (UMEII)Anxiety Disorders | Social Anxiety DisorderSweden
-
Karolinska InstitutetCompletedObsessive Compulsive Disorder | Autism Spectrum DisorderSweden
-
Karolinska InstitutetCompletedObsessive-Compulsive DisorderSweden
-
Karolinska InstitutetBUP ÖstersundCompletedGeneralized Anxiety Disorder | Specific Phobia | Separation AnxietySweden
-
Eva SerlachiusRegion StockholmCompletedObsessive-Compulsive DisorderSweden
-
Karolinska InstitutetCompletedFunctional Abdominal Pain DisordersSweden
-
Karolinska InstitutetCompletedObsessive-Compulsive DisorderSweden
-
Karolinska InstitutetRegion Stockholm; Aleris Helse; Allmänna arvsfonden; Königska-Söderströmska sjukhemmetCompletedIrritable Bowel SyndromeSweden